Temozolomide Accord 5 mg hard capsules.

DRUG3 trials

Sponsors

Institut De Recherches Internationales Servier IRIS, Medical University Of Vienna, Universitair Medisch Centrum Utrecht

Conditions

Diffuse Midline GliomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant Gliomaependymoma and atypical teratoid rhabdoid tumor (ATRT)rare CNS tumorsrecurrent/progressive medulloblastoma

Phase 1

A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma

Active, not recruitingCTIS2024-513738-39-00

Institut De Recherches Internationales Servier IRISIDH1-mutant Glioma, IDH2-mutant Glioma

Start: 2025-03-18Target: 17Updated: 2025-12-18

FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial

Not yet recruitingCTIS2025-520814-78-00

Universitair Medisch Centrum UtrechtDiffuse Midline Glioma, H3K27-altered

Target: 20Updated: 2026-03-23

Phase 2

MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors

RecruitingCTIS2024-515626-92-00

Medical University Of Viennaependymoma and atypical teratoid rhabdoid tumor (ATRT), rare CNS tumors, recurrent/progressive medulloblastoma

Start: 2013-10-18Target: 100Updated: 2025-11-28